Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 narsoplimab study in pediatric high-risk HSCT-TMA
NL-OMON56242Phase 2Recruiting
- Sponsor
- Omeros Corporation
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of narsoplimab in thrombotic microangiopathies (TMA) and transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Omeros Corporation. Primary endpoint: 100-day survival rate. Started Mar 2024; status: recruiting.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathies (TMA)transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NL-OMON56242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56242.